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Transplantation therapy for diabetes is limited by unavailability of donor organs and outcomes complicated by immunosuppressive
drug toxicity. Xenotransplantation is a strategy to overcome supply problems. Implantation of tissue obtained early during
embryogenesis is a way to reduce transplant immunogenicity. Insulin-producing cells originating from embryonic pig pancreas
obtained very early following pancreatic primordium formation (embryonic day 28 (E28)) engraft long-term in non-immune,
suppressed diabetic rats or rhesus macaques. Morphologically, similar cells originating from adult porcine islets of Langerhans
(islets) engraft in non-immune-suppressed rats or rhesus macaques previously transplanted with E28 pig pancreatic primordia.
Our data are consistent with induction of tolerance to an endocrine cell component of porcine islets induced by previous
transplantation of embryonic pig pancreas, a novel finding we designate organogenetic tolerance. The potential exists for its use to
enable the use of pigs as islet cell donors for humans with no immune suppression requirement.

1. Introduction
We have reviewed previously, for J. Transplantation, why
transplantation of embryonic pancreatic primordia to
replace endocrine pancreas function is advantageous relative
to transplantation of either pluripotent embryonic stem
(ES) cells, or of terminally diﬀerentiated (adult) organs
[1]: (1) unlike ES cells, pancreatic primordia diﬀerentiate
along defined lines without a need to steer diﬀerentiation;
(2) there is no risk of teratoma formation; (3) the growth
potential of cells within embryonic pancreas is enhanced
relative to those in the terminally diﬀerentiated organ; (4)
the cellular immune response to transplanted embryonic
pancreas is attenuated relative to that directed against the
adult organ; (5) the ability of avascular primordia to attract
a host blood supply renders them less susceptible to humoral
rejection than is donor-vascularized adult pancreas after
transplantation across a discordant xenogeneic barrier; and
(6) exocrine pancreatic tissue does not diﬀerentiate following

transplantation of embryonic pancreas, obviating inflammatory complications that result from exocrine components.
Transplantation of human embryonic pancreas in human
hosts has been contemplated [2]. However, we [3–8] and
others [9–12] have focused on the use of embryonic
pancreas from the pig, a physiologically suitable donor for
humans [13, 14]. Glucose tolerance can be normalized in
streptozotocin- (STZ-) diabetic (type 1) LEW [3, 4, 7] rats
or ZDF (type 2) diabetic rats [5] within 4 weeks following
transplantation in mesentery of pig pancreatic primordia
obtained very early during embryogenesis (on embryonic
day 28 (E28)—just after the organ diﬀerentiates and prior
to the time dorsal and ventral anlagen fuse) without
host immune suppression. Rats are rendered permanently
independent of a requirement for exogenous insulin to
maintain normoglycemia. No circulating rat insulin can be
detected in STZ-treated rats. Rather, porcine insulin circulates aftertransplantation of E28 pig pancreatic primordia
levels of which increase after a glucose load. Cells with beta
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cell morphology expressing insulin and porcine proinsulin
mRNA engraft in host mesentery, mesenteric lymph nodes,
liver, and pancreas aftertransplantation.
Cells originating from E28 pig pancreatic primordia
transplanted in mesentery engraft similarly in non-immunesuppressed STZ-diabetic rhesus macaques [6, 8]. Glucose tolerance can be nearly normalized in non-immunesuppressed diabetic macaques following transplantation of
E28 pig pancreatic primordia [1]. Porcine insulin, but not
primate insulin, circulates after transplantation in macaques
[6]. Exogenous insulin requirements are reduced in transplanted macaques [6]. Animals have been weaned oﬀ insulin
for short periods of time, but not permanently [1]. The most
likely explanation for the diﬀerential success between rats
and macaques is that macaques weigh 20 times as much
as rats. A STZ-diabetic rat can be rendered normoglycemic
lifelong with no exogenous insulin requirement by transplantation of 5–8 pig pancreatic primordia. Extrapolating,
it would take 100–200 primordia to render a diabetic
macaque independent of exogenous insulin. This would
require the sacrifice of about 10–20 pregnant sows and
multiple surgeries with the attendant complications [7].
In lieu of increasing the numbers of transplanted primordia or transplant surgeries in diabetic rhesus macaques, we
embarked on a series of experiments to determine whether
porcine islets, a more easily obtainable and possibly more
robust source of insulin-producing cells, could be substituted
for animals in which embryonic pig pancreas already had
been engrafted. To this end, we implanted adult porcine
islets beneath the capsule of one kidney of rats or macaques,
that several weeks earlier had been transplanted with E28
pig pancreatic primordia in mesentery. We employed the
renal subcapsular site for islet implantation so that we could
diﬀerentiate engrafted porcine tissue originating from the
islets from tissue originating from prior mesenteric E28 pig
pancreatic transplants, that never engraft in host kidney [7,
8]. In this setting, the contralateral (nontransplanted) kidney
served as a control, as did kidneys from rats or macaques
implanted with islets without prior transplantation of E28
pig pancreatic primordia in mesentery [7, 8]. As in experiments demonstrating engraftment of cells originating from
E28 pig pancreatic primordia transplanted in mesentery
of rats or macaques [3–6], we employed multiple are
techniques to ascertain whether cells from porcine islets
engrafted in kidney: immune histochemistry for insulin; in
situ hybridization specific for porcine proinsulin mRNA;
fluorescent in situ hybridization for pig X chromosomes; RTPCR specific for porcine proinsulin mRNA; measurement of
glucose-stimulated insulin release in vitro from implanted
kidney tissue; electron microscopy [7, 8].
Figures 1(a) and 1(b) show sections from a kidney
of a STZ-diabetic rat implanted with porcine islets following transplantation of E28 pig pancreatic primordia in
mesentery. Sections are stained using anti-insulin antibodies
(Figure 1(a)) or control serum (Figure 1(b)). Cells that stain
for insulin (Figure 1(a), arrows), but not with control serum
(Figure 1(b)), are present in an expanded renal subcapsular
space [7]. Figures 1(c)–1(g) show sections from a kidney
of a STZ-diabetic rhesus macaque following transplantation
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Figure 1: Sections of the islet-implanted kidney from a rat (a,
b) or rhesus macaque (c–g) transplanted with E28 pig pancreatic
primordia in mesentery followed by porcine islets in the renal
subcapsular space stained using anti-insulin antibodies (a, c, and
e) or control antiserum (b, d); or hybridized to an antisense (f) or
sense (g) probe for porcine proinsulin mRNA. PT: proximal tubule.
Arrows: positively staining cells (a, c, and e). Scale bars 10 um
(a, b); 15 um (c, d), 7.5 um (e–g). Reproduced with permission
from the American Society for Investigative Pathology [7] and from
Organogenesis [8].

of E28 pig pancreatic primordia in mesentery and subsequent implantation of islets in the kidney. Sections are
stained using anti-insulin antibodies (Figures 1(c) and
1(e)) or control serum (Figure 1(d)) or hybridized to an
antisense (Figure 1(f)) or sense (Figure 1(g)) probe specific
[6] for porcine proinsulin mRNA. As was the case in rats
(Figure 1(a)), a row of cells that stain for insulin is present
in the subcapsular space (Figure 1(c) arrow). A high-power
view of a single insulin-staining cell is shown in Figure 1(e)
(arrow). It is polygonal with a round nucleus, a beta cell
morphology [8]. No staining for insulin is observed in
sections incubated with control antiserum (Figure 1(d)). A
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cell in the subcapsular space to which the antisense porcine
proinsulin mRNA probe binds is shown in Figure 1(f)
(arrow). No hybridization is observed if a sense probe is
substituted for the antisense probe (Figure 1(g)).
Neither cells that stain for insulin nor cells to which the
probe for porcine proinsulin mRNA binds are present in
contralateral (nonimplanted) kidneys of STZ diabetic rats
[7] or macaques [8] in which E28 pig pancreatic primordia
were transplanted previously in mesentery or in kidneys
from STZ-diabetic rats [7] or macaques [8] into which
porcine islets are implanted without prior transplantation of
E28 pig pancreatic primordia in mesentery. Presumably, the
implanted tissue is rejected by the host [7, 8].
To provide additional evidence that cells in the kidneys
of islet-implanted rats or macaques previously transplanted
with E28 pig pancreatic primordia in mesentery are of
porcine origin, we demonstrated using fluorescent in situ
hybridization, that the cells contain pig X chromosomes
[7, 8]. Shown in Figure 2(a) are pig X chromosomes in nuclei
of cells from a normal porcine pancreas (positive control).
Figure 2(b) shows pig X chromosomes (arrows) in the nuclei
of cells in the renal subcapsular space (arrowheads) from
a STZ diabetic rhesus macaque transplanted with E28 pig
pancreatic primordia in mesentery followed by porcine islets
in kidney.
Multiple organs were excised from a STZ-diabetic
macaque transplanted with E28 pig pancreatic primordia
in mesentery and subsequently with porcine islets in the
renal subcapsular space of one kidney. Tissues were homogenized individually and total RNA was purified. RT-PCR
was performed using primers specific for pig or monkey
proinsulin mRNA. Products were separated by electrophoresis on 3% agarose gels and their identities confirmed by
sequencing in the Washington University Core Protein and
Nucleic Acid Chemistry Laboratory [8]. Results are shown
in Figure 3(a). The pig primers amplify a band of 193 bps
in RNA originating from pig pancreas, corresponding to pig
proinsulin insulin mRNA. The rhesus macaque (monkey)
primers amplify a band of 199 bps corresponding to monkey
proinsulin mRNA in monkey pancreas. Pig proinsulin

250
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Figure 2: Fluorescence microscopy of tissue sections originating
from (a) a normal porcine pancreas or (b) a subcapsular section
from a kidney of a rhesus macaque transplanted with embryonic pig
pancreas in mesentery and subsequently with porcine islets in that
kidney. PT: proximal tubule, arrows: delineate pig X chromosomes.
Arrowheads: renal capsule (b). Scale bar 10 um. Reproduced with
permission from Organogenesis [8].

Mr

(b)

Mr

(a)

Pig pancreas 1 ug

PT

Monkey kidney. 1 ug

(PinsExonF2 + PinsExonR2) (Mmins1F2 + MminsR2)

200
175
150
125
100
(b)

Figure 3: RT-PCR: (a) shown left to right are DNA molecular
weights (Mr); amplification of bands using primers specific for
porcine proinsulin from 1 ug RNA extracted from pig pancreas
or from a rhesus macaque (monkey) transplanted with E28 pig
pancreatic primordia in mesentery followed by implantation of
porcine islets in the renal subcapsular space: kidney, heart, spleen,
lung, a negative control for porcine-specific primers (no RNA);
amplification of bands using primers specific for monkey proinsulin
from 1 ug of pig pancreas RNA; monkey pancreas; a second
negative control for macaque-specific primers. (b) Shown left to
right are DNA molecular weights (Mr); amplification of bands
using primers specific for porcine proinsulin from 2 ug RNA
extracted from pig pancreas or from a rhesus macaque (monkey)
implanted with porcine islets in the renal subcapsular space with no
previous transplantation of E28 pig pancreatic primordia: kidneys,
mesenteric lymph node (MLN) spleen, liver, a negative control for
porcine-specific primers (no RNA); amplification of bands using
primers specific for monkey proinsulin from 2 ug of pig pancreas
RNA; monkey pancreas and a second negative control for macaquespecific primers. Pig primers amplify a 193 bps band. Monkey
primers amplify a 199 bps band. Reproduced with permission from
Organogenesis [8].
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2. Discussion
The shortage of human pancreas donor organs imposes
severe restrictions on the use of allotransplantation to treat
diabetes mellitus [15–22]. When performed, whole pancreas
transplantation requires use of potent immunosuppressive
medications that have significant complications. Newer,
more targeted immunosuppressive regimens that do not
require steroids or high-dose calcineurin inhibitors make
islet transplantation a more attractive option. However, side
eﬀects of immune suppression that must be maintained so
long as the islet graft functions remain a source of morbidity
and even mortality [15]. Thus transplantation therapy for
diabetes trades one set of morbidities (associated with
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mRNA is also detected in the islet-implanted monkey kidney.
Multiple organs were excised from a STZ-diabetic macaque
transplanted with porcine islets in the renal subcapsular
space of one kidney with no prior transplantation of E28 pig
pancreatic primordia in mesentery and RT-PCR performed
as above. As shown in Figure 3(b), no pig proinsulin mRNA
was detected in any monkey organ including the transplanted
kidney.
To ascertain whether cells originating from kidneyimplanted porcine islets function in rats or rhesus macaques,
we determined whether the glucose tolerance of STZ-diabetic
animals normalized partially by prior transplantation of E28
pig pancreatic primordia in mesentery was rendered normal
by subsequent islet implantation, and measured glucosestimulated insulin release from islet-implanted kidneys in
vitro. Rats were rendered fully glucose tolerant by subsequent
implantation of porcine islets in one kidney [7]. The glucose
tolerance of macaques normalized partially by prior transplantation of E28 pig pancreatic primordia in mesentery was
not improved by subsequent implantation of islets in kidney
[8]. However, a rapid release of insulin by macaque kidney
slices was demonstrated in vitro in response to elevation of
glucose levels across the threshold for insulin release [8].
As illustrated in a representative of 3 experiments using
weight-matched tissue, no insulin could be detected at time
0 in supernatants from the implanted macaque kidney
(Figure 4(a)). However, insulin was detectable by 1 min after
increasing the glucose level in vitro. No insulin was detected
at any time in any supernatants from the nonimplanted
kidney (Figure 4(b)), or in supernatants from a kidney of
a macaque in which porcine islets were implanted without
prior transplantation of E28 pig pancreatic primordia in
mesentery [8].
Cells containing endocrine granules in an expanded
renal subcapsular space were identified in electron micrographs of kidneys from rats implanted with porcine islets
following transplantation of E28 pig pancreatic primordia
in mesentery [7]. Figure 5 is an electron micrograph of the
subcapsular space from a rhesus macaque kidney into which
porcine islets were implanted following transplantation of
E28 pig pancreatic primordia in mesentery. Shown is a
cell with encapsulated granules (arrows) characteristic of
endocrine secretory granules [8].
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Figure 4: Levels of insulin (uU/mL) measured over 60 min in
vitro after addition of glucose to tissue following time 0: (a) from
a macaque kidney implanted with porcine islets following transplantation of E28 pig pancreatic primordia in mesentery; (b) the
contralateral nonimplanted kidney. Reproduced with permission
from Organogenesis [8].

Figure 5: Electron micrograph of rhesus macaque kidney following
sequential transplantation of E28 pig pancreatic primordia in
mesentery and implantation of porcine islets in the kidney. Arrows:
endocrine granules. Scale bar a 2 um. Reproduced with permission
from Organogenesis [8].

diabetes and its medical treatment) for another (associated
with immune suppression).
The severity of humoral rejection eﬀectively precludes
the use of pigs as whole pancreas organ donors for
humans. However, because they are vascularized by the
host posttransplantation, islets like other cell transplants
are not subject to humoral rejection. Porcine islets are
rejected within two weeks of transplantation in non-immune
suppressed non-human primates [8, 16–18]. Experience
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with pig to primate islet or neonatal islet transplantation
in immune suppressed non-human primates shows that
sustained insulin independence can be achieved, but only
through the use of agents that are not approved for human
use or that result in a high level of morbidity and mortality
[19–21]. Thus, the need for host immune suppression is a
barrier for pig-to-human islet xenotransplantation.
Xenotransplantation of embryonic pig pancreatic primordia in lieu of mature pig organs or porcine islets couples
the wide availability of pig organs with the immunological
advantages inherent in transplanting cellular embryonic
tissue, circumventing humoral rejection and obviating the
need for host immune suppression [1]. However, obtaining
embryonic pig pancreata is technically challenging because
surgery must be performed on multiple pregnant sows and
isolation carried out from scores of embryos to obtain
suﬃcient numbers of primordia. Furthermore, transplanting
pancreatic primordia in mesentery of primates is invasive,
requiring that a host laparotomy be performed on one or
more occasions. In contrast, porcine islets can be isolated in
large quantities from a single pig pancreas, and infusion of
porcine islets can be carried out via the portal vein infusion
without a laparotomy [22].
Cells from porcine islets do not survive afterimplantation
in rat or macaque kidneys without prior transplantation of
E28 pig pancreatic primordia transplantation in mesentery
[7, 8]. Whole porcine islets do not engraft in kidneys. Rather,
an endocrine (beta cell) component originating from porcine
islets does so [7, 8]. Ours is the first report describing
sustained survival of such cells following transplantation
of porcine islets in non-immune-suppressed primates. Glucose tolerance in diabetic rats not fully normalized by
prior transplantation of E28 pig pancreatic primordia in
mesentery is corrected following subsequent implantation
of porcine islets in kidney [7]. In contrast, correction is
not observed following E28 pig pancreatic primordia transplantation and porcine islets implantation in macaques [8];
that is, consistent with previous observations that glucose
tolerance is more diﬃcult to correct in macaques than in
rats [6]. It is possible that the cell component, although of
suﬃcient mass to normalize glucose tolerance in diabetic rats
following implantation of islets [7], is insuﬃcient following
implantation in rhesus macaques [8]. Implantation of more
islets (isolated from more than one adult pig pancreas)
in kidney or infusion of porcine islets into a site from
which insulin can act more directly on liver (the portal
vein) [22] following transplantation of E28 pig pancreatic
primordia in mesentery may be a better way to normalize
glucose tolerance. Alternatively, it may be that the mass of
engrafted cells originating from porcine islets implanted in
kidney (perhaps derived from a numerically small stem cell
component within the islets) [7, 8] is insuﬃcient to impact
on control of circulating glucose in an animal as large as a
macaque.
Schroeder et al. [23] define transplantation tolerance as
immune unresponsiveness to the transplanted organ, but not
to other antigens in the absence of ongoing immunosuppression. Lewis rats transplanted with E28 pig pancreatic
primordia retain reactivity to other porcine xenoantigens
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(E28 pig renal primordia are rejected [4]). Thus, our
findings are consistent with induction of specific tolerance
[23] to a cell component (either beta cells or a stem cell
component that diﬀerentiates into insulin-producing cells)
of adult porcine islets implanted in Lewis rats by previous
transplantation of E28 pig pancreatic primordia.
Engraftment of pancreatic progenitors transplanted
across a xenogeneic barrier to non-immune-suppressed
immune-suﬃcient hosts has been reported twice previously.
Eloy et al. described normalization of glucose posttransplantation of E15, but not E18 embryonic chick pancreas
into liver of non-immune-suppressed STZ-diabetic rats [24].
Abraham et al. [25] described successful xenoengraftment in
multiple organs of human pancreatic islet-derived progenitor cells infused in nonimmunosuppressed mice. Neither
Eloy et al. [24] and Abraham et al. [25] nor we [3–
8] define an immunological mechanism for the finding.
Although the antigenicity of fetal tissues may be less than
that of corresponding adult tissues, animal data suggest the
reduction is not enough by itself to ensure permanent graft
survival [26]. Thus, the use of embryonic tissue (pancreas)
per se cannot explain the results.
Host immune suppression is required for successful
engraftment of embryonic pig pancreas in rodents [11] or
non-human primates [12] carried out using methodology
alternative to ours. Therefore, it is likely that one or
more factors in the methodology we employ [3–5, 7],
diﬀerent from that used by others (the protocol of TchorshYutsis et al.) [11], are critical for engraftment without
an immune suppression requirement. Such factors include
those listed in Table 1 for studies that employ rats as hosts
for pancreatic primordia. First, the developmental stage of
donor pig embryos from which primordia are obtained
impacts on the host immune response. We have shown
that E35 pig pancreatic primordia are rejected in Lewis
rats following transplantation, employing conditions under
which E28 or E29 pig pancreatic primordia are engrafted
[4]. While we have no experience transplanting E42 pig
pancreatic primordia in rats, the preferred stage for studies
described by Tchorsh-Yutsis et al. [11], we would expect
them to reject based on our experience with E35 pancreatic
primordia [4]. Second, it is likely that that incubation of
embryonic pancreas prior to transplantation with one or
more growth factors and cytokines (iron-saturated transferrin; prostaglandin E1 and vascular endothelial growth
factor; hepatocyte growth factor) [3–5, 7] alters the host
immune response. Tchorsh-Yutsis et al. do not employ
such agents [11]. Third, it is possible that hyperglycemia
in diabetic hosts [3–5, 7] impairs the immune response
to embryonic pancreas. Tchorsh-Yutsis et al. transplant
pancreatic primordia into nondiabetic rats [11]. Fourth, the
transplantation site and technique probably impacts on the
host immune response. We interpose pancreatic primordia
between sheets of mesentery [3–5, 7]. Tchorsh-Yutsis et
al. transplant into pockets of omentum and secure using
suture [11], the latter in itself likely to trigger inflammation.
We have proposed [27] that transplantation of E28 pig
pancreatic primordia in the mesentery and migration of cells
to mesenteric lymph nodes and liver recapitulates events
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Table 1: Methodology employed for transplantation of embryonic pig pancreas in immune suﬃcient non-immune-suppressed rats.

Developmental stage of donors
Incubation prior to transplantation
Diabetic status of the host
Transplantation site

References [3–5, 7]
E28 preferred, E29
Growth factors & cytokines
Diabetic
Interposed within mesentery

that occur during induction of oral tolerance [28–30], which
is dependent on antigen transport via aﬀerent lymphatics
into the draining mesenteric lymph nodes [30]. In eﬀect,
we suggest that heterotopic introduction of embryonic pig
pancreas in rat or primate mesentery coopts the function
of the gut-associated lymphoid tissues (GALT), a complex,
redundant [28–30], and phylogenetically ancient system [31,
32] of which embryonic pancreas is a part [33], that, under
normal conditions, induces peripheral tolerance to ingested
antigens in jawed vertebrates and their descendants.
Interestingly, GALT may have served similarly to prevent
an immune response to insulin-producing cells scattered
originally in the gut epithelium of primitive vertebrates
[31, 32] and has been proposed to induce tolerance or
immune suppression towards islet cell antigens during
normal embryonic development [33]. Developmentally controlled lymphogenesis establishes a preferential traﬃcking
route from the gut to pancreatic lymph nodes, a GALT
component, in which T cells can be activated by antigens
drained from the peritoneum and the gastrointestinal tract.
Intestinal stress modifies the presentation of pancreatic selfantigens in pancreatic lymph nodes. The convergence of
endocrine and intestinal contents at this site may explain
the link between an autoimmune pathogenesis for type
1 diabetes and environmental provocation [33, 34]. Low
doses of orally administered antigen induce antigen-specific
peripheral tolerance through active suppression of T cells
and induction of clonal anergy. High doses induce tolerance
by extrathymic deletion of antigen-reactive T cells [35].
It was proposed originally that oral tolerance depends
exclusively on antigen uptake by cells within intestinal Peyer’s
Patches [30]. However, recently it has been shown that highdose oral tolerance can be induced in the absence of Peyer’s
Patches so long as mesenteric lymph nodes are present [30,
36].
Harada et al. have proposed a similar coopting of oral
tolerance to explain the muted immune response in vivo
and by cells from mesenteric lymph nodes in vitro to a
colon carcinoma of BALB/c origin or a human CD80transfected DBA/2 mastocytoma injected into the subserosal
space of cecum in BALB/c mice relative to tumors injected
subcutaneously [37].
One way to confirm a causative link between gut
immunity and our ability to transplant E28 pig pancreatic
primordia and porcine islets in non-immune-suppressed
hosts would be to “break” the established oral tolerance
[38], using glucose control as a readout in the rat mode,
theoretically possible so long as extrathymic deletion of
antigen-reactive T cells [35] has not occurred.

Reference [11]
E28, E42 preferred
None
Nondiabetic
Sutured in omentum

In any case, we have demonstrated in two species [7, 8],
a novel finding that prior transplantation of embryonic
tissue (pancreas) enables engraftment of a cell component from diﬀerentiated adult tissue from the same organ
(islets) transplanted subsequently, without the need for
host immune suppression, a phenomenon, the immunologic
mechanism for which remains undefined, that we term
organogenetic tolerance [27]. Applicability of the finding to
organ replacement therapy in humans awaits definition. The
potential exists for its use to enable the use of pigs as islet cell
donors for humans with a need for no immune suppression.
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